Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Cardiology | Family Medicine | Internal Medicine | Nursing | Pharmacy | Journal

Back to Journal Articles

Similar Rate of CV Events With Atenolol, Metoprolol Tartrate

Last Updated: August 30, 2012.

 

Rates of incident heart attack, stroke, heart failure similar for newly medicated patients with HTN

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
There are no significant differences in the rates of incident myocardial infarction, heart failure, or stroke for patients with hypertension starting treatment with atenolol or metoprolol tartrate, according to a study published online Aug. 27 in the Archives of Internal Medicine.

THURSDAY, Aug. 30 (HealthDay News) -- There are no significant differences in the rates of incident myocardial infarction (MI), heart failure, or stroke for patients with hypertension starting treatment with atenolol or metoprolol tartrate, according to a study published online Aug. 27 in the Archives of Internal Medicine.

Emily D. Parker, M.P.H., Ph.D., from the HealthPartners Institute for Education and Research in Minneapolis, and colleagues used electronic health records and health plan data from the Cardiovascular Research Network Hypertension Registry for patients who were new β-blocker users between 2000 and 2009 to examine their effectiveness for preventing cardiovascular events.

The researchers found that, over a median of 5.2 years of follow-up, in a cohort of 120,978 patients there were 3,517 incident cases of MI; 3,272 incident cases of heart failure; and 3,664 incident stroke events. In metoprolol tartrate users, the hazard ratios for MI, heart failure, and stroke were 0.99 (95 percent confidence interval [CI], 0.97 to 1.02), 0.99 (95 percent CI, 0.96 to 1.01), and 0.99 (95 percent CI, 0.97 to 1.02), respectively. The use of propensity score matching yielded similar results in 11,176 new metoprolol tartrate users, who had similar demographic and clinical characteristics as 11,176 new atenolol users.

"In conclusion, we found no differences in cardiovascular event rates when comparing patients without a history of cardiovascular events who were initiating treatment with either atenolol or metoprolol tartrate," the authors write. "These findings suggest that hypertension trial outcomes with atenolol may not relate to unfavorable characteristics of this particular drug."

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Cognitive Decline Worse for Women vs. Men in Alzheimer's Next: Mites, Associated Bacteria Possibly Play Role in Rosacea

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.